Back to top

The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics

Read MoreHide Full Article
For Immediate Release
Chicago, IL – March 19, 2015 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Amgen ((AMGN - Free Report) -Free Report), Regeneron ((REGN - Free Report) -Free Report), Nektar (NKTR-Free Report), ACADIA ((ACAD - Free Report) -Free Report) and Pharmacyclics (-Free Report).
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Wednesday’s Analyst Blog:    

Biotech Stock Roundup
Last week, companies like Amgen ((AMGN - Free Report) -Free Report) and Regeneron ((REGN - Free Report) -Free Report) were present at the American College of Cardiology's (ACC) Annual Scientific Session with data on their PCSK9 inhibitors. Meanwhile, Nektar (NKTR-Free Report) came out with some disappointing late-stage data on its experimental cancer treatment and ACADIA ((ACAD - Free Report) -Free Report) is facing yet another delay in the regulatory filing for its Parkinson’s treatment.
Recap of the Week’s Most Important Stories
1. Nektar came out with disappointing late-stage data on one of its most advanced pipeline candidates – NKTR-102. Top-line results from the phase III BEACON study in advanced breast cancer patients showed that NKTR-102 failed to achieve the primary endpoint of overall survival. Secondary endpoints like objective response rate (ORR) and progression-free survival (PFS) also did not achieve statistical significance in the study. Although Nektar did report improvements in certain patient subgroups, shares were down in pre-market trading.
2. Amgen presented promising long-term data on its PCSK9 inhibitor, evolocumab, at the recently held annual meeting of the ACC. Evolocumab consistently reduced LDL-C or “bad” cholesterol over a one-year period and lowered the rate of cardiovascular events when added to standard of care (Read more: Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data). Evolocumab is currently under regulatory review with the FDA expected to respond by Aug 27.
However, Regeneron and Sanofi are also looking to get their PCSK9 inhibitor, Praluent, approved and could get a head start over Amgen as the FDA action date for their candidate is Jul 24. Regeneron and Sanofi also came out with their own set of promising long-term data (18-month) on Praluent (Read more: Regeneron/Sanofi's PCSK9 Drug Praluent Data Published).
3. There was some good news on the development front for Pharmacyclics (-Free Report) with an Independent Data Monitoring Committee recommending that a late-stage study evaluating Imbruvica in chronic lymphocytic leukemia or small lymphocytic lymphoma patients should be unblinded. The recommendation was based on clinically meaningful and statistically significant treatment benefit observed in the Imbruvica arm (Read more: Pharmacyclics' Imbruvica Encourages in a Phase III Study).
4. ACADIA saw its shares tumbling on news regarding yet another delay in the NDA filing for its experimental Parkinson’s disease treatment, Nuplazid. The company also announced the exit of its CEO (Read more: ACADIA Down on Nuplazid NDA Delay and CEO Resignation).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks                                             
          is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Get the full Report on AMGN - FREE
Get the full Report on REGN - FREE
Get the full Report on NKTR - FREE
Get the full Report on ACAD - FREE
Get the full Report on PCYC - FREE
Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact                                                           
Zacks Investment Research
800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Amgen Inc. (AMGN) - free report >>

Regeneron Pharmaceuticals, Inc. (REGN) - free report >>

ACADIA Pharmaceuticals Inc. (ACAD) - free report >>

More from Zacks Press Releases

You May Like